Heparin Market Analysis

Based on the product, the low molecular weight heparin market was valued at over USD 4.2 billion in 2022. Growing occurrence of deep vein thrombosis has increased the need for low molecular weight heparin. As per CDC, around 60,000-100,000 Americans die of this condition every year. Moreover, low molecular weight heparin has a longer shelf-life, reduces and eliminates hospital stays, and can be self-administered at home via subcutaneous injection, which favors its mass adoption. 

With respect to application, the market size from the venous thromboembolism segment could expand at over 2% CAGR from 2023 to 2032. Growing prevalence of venous thromboembolism has increased the need for heparin. Moreover, recent innovations in the development of novel heparin products to overcome the limitation of current treatment options for venous thromboembolism are further contributing to segment growth. Many industry players are focusing on developing enhanced capabilities of heparin to extend their footprint, creating a robust growth outlook for the heparin industry. 

From the regional perspective, Europe heparin market share reached more than 58.5% in 2022. Growing prevalence of venous thromboembolism, ischemic heart disease, and other cardiovascular diseases that lead to blood clot formation has increased the need for heparin in Europe. As per the European Society of Cardiology, cardiovascular disorders lead to around 3.9 million mortalities annually in the region. Moreover, regional expansion can also be attributed to rising awareness about novel oral anticoagulants.